{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT03408730",
      "orgStudyIdInfo": {
        "id": "Sci-B-Vac-002"
      },
      "secondaryIdInfos": [
        {
          "id": "2017-001820-22",
          "type": "EUDRACT_NUMBER"
        }
      ],
      "organization": {
        "fullName": "VBI Vaccines Inc.",
        "class": "INDUSTRY"
      },
      "briefTitle": "Lot-to-lot Consistency of Sci-B-Vac™ in Adults",
      "officialTitle": "A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)"
    },
    "descriptionModule": {
      "briefSummary": "A Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults",
      "detailedDescription": "The primary objective of the study is to verify that the manufacturing equivalence of Sci-B-Vac™ is consistent and to compare the immunogenicity and safety of a three-dose regimen of Sci-B-Vac™ to a three-dose regimen of Engerix-B® in adults."
    },
    "conditionsModule": {
      "conditions": [
        "Hepatitis B Vaccines"
      ],
      "keywords": [
        "Hepatitis B Vaccines"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "interventionModelDescription": "Double-blind Randomized Controlled Trial",
        "primaryPurpose": "PREVENTION",
        "maskingInfo": {
          "masking": "TRIPLE",
          "whoMasked": [
            "PARTICIPANT",
            "INVESTIGATOR",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 2838,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Sci-B-Vac Lot A Hep B Vaccination",
          "type": "EXPERIMENTAL",
          "description": "Sci-B-Vac Lot A Hepatitis B Vaccination",
          "interventionNames": [
            "Biological: Hepatitis B Vaccination"
          ]
        },
        {
          "label": "Sci-B-Vac Lot B Hep B Vaccination",
          "type": "EXPERIMENTAL",
          "description": "Sci-B-Vac Lot B Hepatitis B Vaccination",
          "interventionNames": [
            "Biological: Hepatitis B Vaccination"
          ]
        },
        {
          "label": "Sci-B-Vac Lot C Hep B Vaccination",
          "type": "EXPERIMENTAL",
          "description": "Sci-B-Vac Lot C Hepatitis B Vaccination",
          "interventionNames": [
            "Biological: Hepatitis B Vaccination"
          ]
        },
        {
          "label": "Comparator: ENGERIX-B Hep B Vaccination",
          "type": "ACTIVE_COMPARATOR",
          "description": "Active Comparator: ENGERIX-B Hepatitis B Vaccination",
          "interventionNames": [
            "Biological: Hepatitis B Vaccination"
          ]
        }
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Hepatitis B Vaccination",
          "description": "Hepatitis B Vaccination",
          "armGroupLabels": [
            "Comparator: ENGERIX-B Hep B Vaccination",
            "Sci-B-Vac Lot A Hep B Vaccination",
            "Sci-B-Vac Lot B Hep B Vaccination",
            "Sci-B-Vac Lot C Hep B Vaccination"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Geometric Mean Concentration (GMC) of Anti-HBs at Day 196 for Lot-to-Lot Consistency (Per Protocol Set 1)",
          "description": "To demonstrate the manufacturing equivalence, in terms of immunogenicity, as measured by GMC of antibodies, of 3 independent consecutive lots of the Sci-B-Vac® 4 weeks after the third vaccination. Lot-to-lot manufacturing consistency of Sci-B-Vac® is demonstrated if the 95% CIs of the adjusted anti-HBs GMC ratios between lots are within the pre-specified range of \\[0.67, 1.5\\].",
          "timeFrame": "4 weeks after third vaccination (Study Day 196)"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Seroprotection Rate (SPR) of Anti-HBs at Day 196 for Sci-B-Vac® Compared to Day 196 for Engerix-B® (Per Protocol Set 2)",
          "description": "The difference in proportions \\[SPR(Sci-B-Vac®)-SPR(Engerix-B®)\\] and two-sided 95% CIs were summarized. If the lower bound of the 95% CI was \\> 5%, Sci-B-Vac® was to be declared non-inferior to Engerix-B®",
          "timeFrame": "4 weeks after third vaccination (Study Day 196)"
        },
        {
          "measure": "Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs)",
          "description": "Analysis of local and systemic solicited adverse events with an interval of onset of Day 1 to Day 7 after any vaccination with either Sci-B-Vac® or Engerix-B®, in adults ≥18 years old.",
          "timeFrame": "Day of vaccine administration and six subsequent days"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Any gender\n* Age 18-45 years\n* Healthy, as determined by a physical examination and values of laboratory tests\n* If female, either is not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), is of childbearing potential and must agree to use an adequate birth control method\n* Able and willing to give informed consent\n\nExclusion Criteria:\n\n* Previous vaccination with any Hep B vaccine (HBV) (licensed or experimental)\n* Treatment by immunosuppressant within 30 days of enrollment\n* History of immunological function impairment\n* Pregnancy or breastfeeding\n* Immunization with attenuated vaccines (e.g. MMR) within 4 weeks prior to enrollment\n* Immunization with inactivated vaccines (e.g. influenza) within 2 week prior to enrolment\n* Has received blood products or immunoglobulin within 90 days of enrollment or is likely to require blood products during the study period\n* Subject in another clinical trial with an investigational drug or a biologic within 30 days of enrollment\n* Has received granulocyte-macrophage colony stimulating factor (G/GM-CSF) or erythropoietin (EPO) within 30 days of enrollment or likely to require GM-CSF or erythropoietin during the study period\n* Any history of cancer requiring chemotherapy or radiation within 5 years of randomization or current disease.\n* Any skin abnormality or tattoo that would limit post-vaccination injection site assessment\n* History of allergic reactions or anaphylactic reaction to any vaccine component\n* Unwilling, or unable in the opinion of the investigator, to comply with study requirements\n* Immediate family members of study center staff\n* Current or past hepatitis B infection or prior vaccination as evidenced by HBV markers\n* Known hepatitis C infection or positive Hepatitis C serology at screening, unless treated and cured\n* Known human immunodeficiency virus (HIV) infection or positive HIV serology at screening\n* Renal impairment with Glomerular Filtration Rate (GFR) \\<90 mL/min/ 1.73 m2 at screening\n* BMI ≥ 35\n* Uncontrolled hypertension\n* Diagnosis of Type 1 or Type 2 diabetes or HbA1C ≥ 6.5% at screening\n* Any laboratory test abnormality that would be considered of Grade 1 severity or above as per FDA guidelines for grading clinical laboratory abnormalities and is considered as clinically significant by the investigator.",
      "healthyVolunteers": true,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "45 Years",
      "stdAges": [
        "ADULT"
      ]
    }
  }
}